Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F. Viola D, et al. Among authors: hofmeister cc. Leukemia. 2021 Jan;35(1):189-200. doi: 10.1038/s41375-020-0810-4. Epub 2020 Apr 16. Leukemia. 2021. PMID: 32296125 Free PMC article.
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM. Pichiorri F, et al. Among authors: hofmeister cc. J Exp Med. 2013 May 6;210(5):951-68. doi: 10.1084/jem.20120950. Epub 2013 Apr 22. J Exp Med. 2013. PMID: 23610125 Free PMC article.
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J. Chu J, et al. Among authors: hofmeister cc. Leukemia. 2014 Apr;28(4):917-27. doi: 10.1038/leu.2013.279. Epub 2013 Sep 26. Leukemia. 2014. PMID: 24067492 Free PMC article.
Circulating miRNA markers show promise as new prognosticators for multiple myeloma.
Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F. Rocci A, et al. Among authors: hofmeister cc. Leukemia. 2014 Sep;28(9):1922-6. doi: 10.1038/leu.2014.155. Epub 2014 May 12. Leukemia. 2014. PMID: 24813918 Free PMC article. No abstract available.
The potential of miRNAs as biomarkers for multiple myeloma.
Rocci A, Hofmeister CC, Pichiorri F. Rocci A, et al. Among authors: hofmeister cc. Expert Rev Mol Diagn. 2014 Nov;14(8):947-59. doi: 10.1586/14737159.2014.946906. Epub 2014 Aug 7. Expert Rev Mol Diagn. 2014. PMID: 25098410 Review.
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC. Sborov DW, et al. Among authors: hofmeister cc. Clin Cancer Res. 2014 Dec 1;20(23):5946-55. doi: 10.1158/1078-0432.CCR-14-1404. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294913 Free PMC article. Clinical Trial.
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Canella A, et al. Among authors: hofmeister cc. Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290. Oncotarget. 2015. PMID: 26429859 Free PMC article.
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F. Stiff A, et al. Among authors: hofmeister cc. Mol Cancer Ther. 2016 May;15(5):830-41. doi: 10.1158/1535-7163.MCT-15-0240-T. Epub 2016 Jan 25. Mol Cancer Ther. 2016. PMID: 26809490 Free PMC article.
151 results